Merck announced today that the HPS2-THRIVE ( H eart P rotection S tudy 2- T reatment of H DL to R educe the I ncidence of V ascular E vents) study did not meet its primary endpoint.

FORBES: HPS2-THRIVE: No Benefit, Signal Of Harm For Niacin Therapy